The effect of probiotic capsule on patients with macular degeneration associated with age

Evaluation of the effects of capsules containing probiotics on metabolic parameters, oxidative stress and clinical symptoms of age-related macular degeneration

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130211012438N30

Enrollment

Registered

2019-02-19

Start date

2018-05-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration. Degeneration of macula and posterior pole

Interventions

Intervention 1: Intervention group: probiotic capsule 500 MG,produced in tak gene company,One number per day for 2 months orally. Intervention 2: Control group: placebo capsule500 MG, produced in Tak

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Reduced vision simply because of AMD

Exclusion criteria

Exclusion criteria: Corneal opacity Diabetes History of retinal vascular disorders History of retina tear History of penetrating trauma

Design outcomes

Primary

Measure	Time frame
High sensitive-Critical Reactive Protein. Timepoint: At the beginning of the study and2 months after the start of the study. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Visual Acuity. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Visual Acuity check with Snellen chart.;Macular thickness. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Central Macular Thickness Evaluate with OCT Instrument.;Fasting plasma glucose. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Triglycerides. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Low density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;High density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Total cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Very low density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Standard formula.;Nitric oxide. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Malondialdehyde. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Glutathion. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Total Anti Oxidant. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Insulin. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: ELISA.;QUICKI. Timepoint: At the beginning of the study an	—

Measure

Time frame

Visual Acuity. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Visual Acuity check with Snellen chart.;Macular thickness. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Central Macular Thickness Evaluate with OCT Instrument.;Fasting plasma glucose. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Triglycerides. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Low density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;High density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Total cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Enzymatic Kits.;Very low density lipoprotein-cholesterol. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Standard formula.;Nitric oxide. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Malondialdehyde. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Glutathion. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Total Anti Oxidant. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: Photospectrometry.;Insulin. Timepoint: At the beginning of the study and 2 months after the start of the study. Method of measurement: ELISA.;QUICKI. Timepoint: At the beginning of the study an

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Farajipoor

Kashan University of Medical Sciences

farajipoor_h@kaums.ac.ir+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026